Onset of bronchodilation and finger tremor induced by salmeterol and salbutamol in asthmatic patients

Jan Lötvall MD PhD, Helen Lunde MD, Nils Svedmyr MD PhD
Department of Clinical Pharmacology, Sahlgrenska University Hospital, Göteborg, Sweden

Recently, inhaled beta-agonists having a prolonged duration of action have been marketed for use in asthma. One of these beta-agonists, salmeterol, has a duration of action of at least 12 h after inhalation. However, the onset of action of salmeterol immediately after inhalation has not been sufficiently investigated. In the present study, the onset of action and tremor-inducing effect of two doses of inhaled salmeterol (50 and 100 µg) were compared with inhaled salbutamol (200 and 400 µg) and placebo. Lung function was measured using forced expiratory volume in 1 s (FEV1), and tremor was measured using a linear accelerometer. With salbutamol there was rapid bronchodilation, both doses producing more than 15% improvement in mean FEV1 within 2 mins of inhalation. With salmeterol, on the other hand, significant bronchodilation was delayed until 7 mins versus placebo, and the full bronchodilation effect was not achieved until 60 mins after inhalation. There was a much more rapid onset of tremor with salbutamol (400 µg) than salmeterol. Therefore, salmeterol cannot be recommended to relieve acute symptoms.

Key Words: Asthma, Bronchodilatation, Salbutamol, Salmeterol

Déclenchement de la bronchodilatation et tremblement des doigts induits par le salmétroïl et le salbutamol chez des patients asthmatiques

Salmeterol est un bêta-agoniste avec bronchodilatation qui se prolonge au moins jusqu’à 12 heures après l’inhalation. Cependant, le début d’action du salmétroïl immédiatement après l’inhalation n’a pas été étudié suffisamment. Dans la présente étude, le début d’action et l’effet de tremblement induit par deux doses de salmétroïl en inhalation (50 et 100 µg) ont été comparés à deux doses de salbutamol en inhalation (200 et 400 µg) et un placebo. On a mesuré la fonction pulmonaire en utilisant le volume expiratoire maximum/seconde (VEMS), et le tremblement a été mesuré au moyen d’un accéléromètre linéaire. Avec le salbutamol, on a noté une bronchodilatation rapide ; les deux doses ont entraîné une amélioration de plus de 15 % du VEMS moyen en moins de deux minutes suivant l’inhalation. Par contre, en ce qui concerne le salmetroïl, une bronchodilatation significative n’est produite que 7 minutes après l’inhalation par rapport au placebo et l’effet bronchodilatateur maximal n’a été atteint que 60 minutes après l’inhalation. Le déclenchement du tremblement était beaucoup plus rapide avec le salbutamol (400 µg) qu’avec le salmétroïl. Le déclenchement de la bronchodilatation était beaucoup plus lent avec le salmétroïl qu’avec le salbutamol. En conséquence, le salmétroïl ne doit pas être recommandé pour soulager les symptômes d’asthme aigus.

Key Words: Asthma, Bronchodilatation, Salbutamol, Salmeterol

Recently, inhaled beta-agonists having a prolonged duration of action have been marketed for use in asthma. One of these beta-agonists, salmeterol, has a duration of action of at least 12 h after a single dose (1). A number of single-dose comparisons between salmeterol and shorter acting beta-agonists such as salbutamol have been reported (2-6) in both healthy individuals and asthmatics. Salmeterol has a substantially longer duration of action than shorter acting compounds such as salbutamol and terbutaline. In a study in normal subjects, salmeterol seemed to have a slower onset of action than salbutamol (2), and in single dose studies in asthmatic subjects, it has been shown that salmeterol has a slower onset of action than salbutamol and formoterol (3).

All beta-agonists, both long and short acting, produce skeletal muscle tremor when given by the inhaled route in high enough doses (4,5). Clinically, it has been reported that terbutaline may have a more pronounced tendency to induce tremor than other agents after both oral and inhaled admini-
station. The mechanism underlying such differences is not clear, but differences in the distribution of the drugs in the lung and absorption kinetics are two possible explanations.

The aim of this study was to evaluate the onset of action of two doses of salmeterol compared with two doses of salbutamol and placebo to extend previous studies to multiple-dose comparisons. Particularly, we wished to evaluate the tremor-inducing effects of each dose, with an objective method using a linear accelerometer (4). We selected the doses of 50 and 100 µg salmeterol, which have been suggested to be equipotent to 200 and 400 µg salbutamol, respectively, for bronchodilation (1,6).

PATIENTS AND METHODS

This study was accepted by the ethics committee in Göteborg, Sweden, and the Swedish Medical Products Agency, Uppsala, Sweden. The study was also performed according to Good Clinical Trial Practice principles, and was monitored accordingly by the sponsor. The aim of the study was explained in detail to each patient, and patients were only included if they provided oral and written consent.

Patients: Asthmatic patients of either sex, between 20 and 70 years of age (inclusive), were included in the study. A reversibility of 15% to 50% in forced expiratory volume in 1 s (FEV1) 15 mins after inhalation of up to 400 µg of salbutamol was required for inclusion. Exclusion criteria were significant cardiovascular disease (heart failure, cardiomyopathy, severe angina pectoris), uncontrolled diabetes mellitus, significant thyroid, hepatic or renal disease, known neuromuscular disease, pregnancy, hospitalization within 28 days or a significant thyroid, hepatic or renal disease, known neuromuscular disease, pregnancy, hospitalization within 28 days or a

RESULTS

Sixteen patients, 24 to 64 years of age, were included in the study, but four patients had to be excluded during the course of the study, due to improvement in basal lung function greater than 15% compared with the inclusion visit. The 12 patients who completed the study (nine females), had a mean baseline FEV1 of 2.48 (SEM 0.31; range 1.12 to 4.62), and a mean reversibility of 20.3% (SEM 1.3; range 15 to 27). All patients except one used inhaled glucocorticoids (mean dose 727 mg, range 0 to 1600). Friedman’s test showed a significant variance for percent-age change in FEV1 after the different treatments (P<0.001). All doses of salmeterol and salbutamol produced significant improvement in FEV1 compared with placebo (P<0.003 for all treatments; Figure 1 top). Salmeterol 50 µg produced a significantly smaller maximal improvement in FEV1 than 100 µg (Figure 1 bottom; P<0.03), and a numerically smaller maximal improvement in FEV1 than either dose of salbutamol. This smaller maximal improvement in FEV1, however, was not statistically significant (P=0.11 and P=0.06 compared with 200 and 400 µg salbutamol, respectively). Salmeterol had a very rapid onset of action by more than ±15% mean improvement in FEV1 by 2 mins of inhalation (Figure 1 bottom). Salmeterol, on the other hand, had a significantly slower onset of action than salbutamol, with less bronchodilation achieved at 25 mins after 50 µg compared with 200 µg salbutamol (Figure 1 bottom; P<0.003).

Friedman’s test showed a significant variance for the tremor ratio after the different treatments (P<0.001). Salmeterol 100 µg, and salbutamol 200 and 400 µg produced a significant increase in tremor compared with placebo, but salmeterol 50 µg did not (Figure 2 top; P=0.012, P=0.008,
P=0.002 and P=0.27, respectively). The maximal tremor-inducing effect of salbutamol 200 µg was not significantly different from that of salmeterol 50 µg (P=0.27). In a comparison between the higher doses of the two drugs, the greater tremor inducing effect of salbutamol (Figure 2) almost reached statistical significance (P=0.06). The onset of tremor following use of salbutamol and salmeterol are shown in Figure 2. Salbutamol 400 µg had a more rapid onset of action than either dose of salmeterol (Figure 2 bottom). One patient reported tremors as an adverse event after salmeterol 100 µg, and three patients after salbutamol 400 µg.

**DISCUSSION**

In this study, we have confirmed that salmeterol has a slower onset of bronchodilation than salbutamol. A dose-dependent tremor-inducing effect of both salbutamol and salmeterol was found, the effect for salmeterol being much slower in onset.

In two earlier studies, salmeterol 50 and salbutamol 200 µg were found to be approximately equipotent for maximal improvement in lung function (1). In this study, we found that both doses of salbutamol, and the higher dose of salmeterol, produce similar and probably close to maximal bronchodilation. We were able to document that the lower dose of salmeterol (50 µg) was significantly less effective than the higher dose of salmeterol (100 µg), and there was a tendency towards a smaller effect of this dose of salmeterol compared with both doses of salbutamol. Thus, our results suggest that the four times higher potency of salmeterol than salbutamol, proposed by earlier studies, may be an overestimate, and that the differences in potency probably are smaller. In a complex study design, Smyth and colleagues (7) performed a dose-response study comparing salbutamol with salmeterol, and suggested that salmeterol was up to 10 times more potent than salbutamol weight for weight. Thus, in contrast to our present data, it was proposed that salmeterol 50 µg was equipotent to 500 µg salbutamol, especially concerning improvement in FEV1. However, the comparison of dose-equivalence was between a single dose of salmeterol and cumulative doses of salbutamol, and we would argue that this
comparison is not valid because of the different protocols used for the two drugs.

The slower onset of action of salmeterol is consistent with a previous study (8), where it was found that reversal of methacholine-induced bronchoconstriction was slower for salmeterol than salbutamol. This finding also appears consistent with older studies that suggested a slower onset of bronchodilation with salmeterol (1,9). The slower bronchodilator properties strengthen the recommendation that salmeterol should not be used as rescue medication in asthma. However, it is clear that the bronchodilator properties of both salmeterol and salbutamol are maintained during long term treatment with salmeterol (9-11).

In two previous studies (1,7), only a very high dose of salmeterol (200 µg) was found to produce subjective tremor. In the present study, three patients experienced tremor after 400 µg salbutamol, whereas only one patient experienced tremor after 100 µg salmeterol, further implying a weak tremor-inducing effect of clinically used doses of salmeterol (12). However, in a previous study that was not placebo controlled (1), a dose-related tremor-inducing effect of salmeterol at doses of 100 and 200 µg was observed, evaluated objectively with an accelerometer. In the present study, both doses of salbutamol and the higher dose of salmeterol produced a significantly increased tremor ratio than placebo, but a much more rapid onset of the tremor was observed with salbutamol. This rapid onset of the tremor may be important for inducing subjective experience. However, larger studies would be required to evaluate further any differences between salbutamol and salmeterol regarding this side effect.

ACKNOWLEDGEMENT: This study was sponsored by Glaxo Sweden AB.

REFERENCES